Post-Market Drug Evaluation Advisory Committee

PMDE Industry Task Force (Interim)

CADTH is establishing a time-limited industry task force to identify opportunities and barriers for using industry real-world data (RWD) in our Post-Market Drug Evaluation (PMDE) Program, building upon the recently released Guidance for Reporting Real-World Evidence.

This group is task-oriented and will work collaboratively to develop a summary report for CADTH. This report will advise on best practices and potential approaches for using industry RWD as well as identify ways to mitigate risks and barriers. The summary report will include proposed approaches that will be considered by the PMDE Advisory Committee and CADTH. CADTH intends to share information about the industry task force and the options paper with its stakeholders.

Membership
Facilitator
Don Husereau	Adjunct Professor, University of Ottawa, SEPH
Industry Representatives
Véronique Gaudet	Field Medical Advisor, Bausch Health
Virginie Giroux (Industry Lead)	Director, Health Economic and Outcomes Research, Merck
Jennifer Glass	RWE Lead Canada, Eli Lilly
Nikolas Goyert-Stephens	Senior Manager, Market Access, Biogen
Jason Lee	Head of Market Access and Stakeholder Relations, Amylyx
Maria Luckevich	Health Economics Associate Director, Novo Nordisk
Kevin Pollock	Director of Real-World Evidence, International Markets, Bristol Myers Squibb
Subra Seshadri	Manager Access for Anti-Virals and Hospital Business, Pfizer
Jefferson Tea	Vice-President Medical and Scientific Affairs, Takeda
Jennifer Wu	Health Data Strategy Lead, Roche
Health Canada
Kelly Robinson	Director General, Marketed Health Products Directorate, Health Canada
CADTH Representatives
Tarry Ahuja (CADTH Lead)	Director, Post-Market Drug Evaluation
Trish Caetano	Director, Drug Data Services and Analytics
Peter Dyrda	Director, Pharmaceutical Policy and HTA
Farah Husein	Director, Science and Methods
Brendan McIntosh	Drug Program Advisor, Pharmaceutical Reviews
David Stock	Scientific Advisor, Post-Market Drug Evaluation
Nadine Sulatycky	Program Lead, Post-Market Drug Evaluation